Stoke Therapeutics’ $112 Million Common Stock Offering

Davis Polk advised the representatives of the underwriters in the offering.

Stoke Therapeutics, Inc. completed the $112 million public offering of 2,500,000 shares of common stock, which includes 375,000 shares from the full exercise of the underwriters’ option to purchase additional shares.

Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. Stoke is listed on the Nasdaq Global Select Market under the symbol “STOK.”

The Davis Polk capital markets team advising J.P. Morgan Securities LLC, Cowen and Company, LLC and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters, included partner Deanna L. Kirkpatrick (Picture) and associates Jennifer Ying Lan and Alexa Póo. Partner David R. Bauer and associate Michael V. Policastro provided intellectual property advice. The tax team included partner Michael Mollerus and associate Erin van Wesenbeeck. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell; Alexa Póo – Davis Polk & Wardwell; Erin van Wesenbeeck – Davis Polk & Wardwell; Jennifer Ying Lan – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; Credit Suisse Securities (USA) LLC; J.P. Morgan Securities LLC;

Author: Ambrogio Visconti